<DOC>
	<DOC>NCT02450812</DOC>
	<brief_summary>This observational prospective single arm cohort study is designed to assess overall survival, symptomatic skeletal event free survival and quality of life of of chemotherapy na√Øve metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium- 223 under real life conditions. In addition, time to next tumor treatment (TTNT), mobility, quality of life and selfcare, independence in activities of daily living and safety will be assessed.</brief_summary>
	<brief_title>Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Male patients diagnosed with castration resistant adenocarcinoma of the prostate (CRPC) with symptomatic bone metastases without known visceral metastases Decision to initiate treatment with Radium223 was made as per investigator's routine treatment practice Patients participating in an investigational program with interventions outside of routine clinical practice and also in all noninterventional studies focusing on Radium 223dichloride. Pretreatment with cytostatics (chemotherapy)</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>mCRPC</keyword>
</DOC>